image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 6.14
-4.66 %
$ 201 M
Market Cap
-6.75
P/E
1. INTRINSIC VALUE

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.[ Read More ]

The intrinsic value of one SERA stock under the base case scenario is HIDDEN Compared to the current market price of 6.14 USD, Sera Prognostics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SERA

image
FINANCIALS
306 K REVENUE
14.18%
-39.8 M OPERATING INCOME
12.77%
-36.2 M NET INCOME
17.98%
-27.2 M OPERATING CASH FLOW
21.44%
438 K INVESTING CASH FLOW
-92.11%
752 K FINANCING CASH FLOW
14940.00%
29 K REVENUE
20.83%
-8.86 M OPERATING INCOME
4.23%
-7.92 M NET INCOME
4.62%
-7 M OPERATING CASH FLOW
-18.00%
4.9 M INVESTING CASH FLOW
-4.87%
117 K FINANCING CASH FLOW
-90.28%
Balance Sheet Decomposition Sera Prognostics, Inc.
image
Current Assets 61.3 M
Cash & Short-Term Investments 49.1 M
Receivables 11.5 M
Other Current Assets 795 K
Non-Current Assets 34.1 M
Long-Term Investments 30.8 M
PP&E 3.18 M
Other Non-Current Assets 77 K
Current Liabilities 24.4 M
Accounts Payable 1.05 M
Short-Term Debt 1.02 M
Other Current Liabilities 22.4 M
Non-Current Liabilities 840 K
Long-Term Debt 840 K
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall Sera Prognostics, Inc.
image
Revenue 306 K
Cost Of Revenue 210 K
Gross Profit 96 K
Operating Expenses 39.9 M
Operating Income -39.8 M
Other Expenses -3.58 M
Net Income -36.2 M
RATIOS
31.37% GROSS MARGIN
31.37%
-13013.40% OPERATING MARGIN
-13013.40%
-11843.79% NET MARGIN
-11843.79%
-51.66% ROE
-51.66%
-37.97% ROA
-37.97%
-56.76% ROIC
-56.76%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Sera Prognostics, Inc.
image
Net Income -36.2 M
Depreciation & Amortization 900 K
Capital Expenditures -128 K
Stock-Based Compensation 5.27 M
Change in Working Capital 3.52 M
Others 3.37 M
Free Cash Flow -27.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Sera Prognostics, Inc.
image
SERA has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Sera Prognostics, Inc.
image
Sold
0-3 MONTHS
505 K USD 7
3-6 MONTHS
548 K USD 7
6-9 MONTHS
2.05 M USD 6
9-12 MONTHS
556 K USD 6
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
6 days ago
Nov 11, 2024
Sell 695 USD
Mirza Mansoor Raza
Director
- 95
7.32 USD
6 days ago
Nov 11, 2024
Sell 88.4 K USD
Lindgardt Zhenya
Chief Executive Officer
- 12075
7.32 USD
6 days ago
Nov 11, 2024
Sell 29.9 K USD
Kearney Paul
Chief Data Officer
- 4078
7.32 USD
6 days ago
Nov 11, 2024
Sell 34.6 K USD
Jackson Benjamin
General Counsel
- 4727
7.32 USD
6 days ago
Nov 11, 2024
Sell 34.6 K USD
Harrison Robert Gardner
Chief Information Officer
- 4727
7.32 USD
6 days ago
Nov 11, 2024
Sell 34.6 K USD
Boniface John J.
Chief Scientific Officer
- 4727
7.32 USD
6 days ago
Nov 11, 2024
Sell 52.6 K USD
Aerts Austin
Chief Financial Officer
- 7179
7.32 USD
1 month ago
Oct 07, 2024
Sell 686 USD
Mirza Mansoor Raza
Director
- 96
7.15 USD
2 months ago
Sep 10, 2024
Sell 38.3 K USD
Aerts Austin
Chief Financial Officer
- 5056
7.57 USD
2 months ago
Sep 10, 2024
Sell 190 K USD
Lindgardt Zhenya
Chief Executive Officer
- 25085
7.57 USD
2 months ago
Sep 06, 2024
Sell 687 USD
Mirza Mansoor Raza
Director
- 96
7.16 USD
3 months ago
Aug 07, 2024
Sell 37.3 K USD
Boniface John J.
Chief Scientific Officer
- 5022
7.42 USD
3 months ago
Aug 07, 2024
Sell 37.3 K USD
Harrison Robert Gardner
Chief Information Officer
- 5022
7.42 USD
3 months ago
Aug 07, 2024
Sell 32.2 K USD
Kearney Paul
Chief Data Officer
- 4333
7.42 USD
3 months ago
Aug 07, 2024
Sell 91.5 K USD
Lindgardt Zhenya
Chief Executive Officer
- 12327
7.42 USD
3 months ago
Aug 07, 2024
Sell 749 USD
Mirza Mansoor Raza
Director
- 101
7.42 USD
3 months ago
Aug 07, 2024
Sell 37.3 K USD
Jackson Benjamin
General Counsel
- 5022
7.42 USD
3 months ago
Aug 07, 2024
Sell 50.2 K USD
Aerts Austin
Chief Financial Officer
- 6760
7.42 USD
5 months ago
Jun 10, 2024
Sell 218 K USD
Lindgardt Zhenya
Chief Executive Officer
- 26867
8.11 USD
5 months ago
Jun 10, 2024
Sell 43.9 K USD
Aerts Austin
Chief Financial Officer
- 5415
8.11 USD
6 months ago
May 15, 2024
Sell 85.6 K USD
Kearney Paul
Chief Data Officer
- 10387
8.24 USD
6 months ago
May 08, 2024
Sell 40.3 K USD
Kearney Paul
Chief Data Officer
- 4205
9.59 USD
6 months ago
May 08, 2024
Sell 47 K USD
Boniface John J.
Chief Scientific Officer
- 4902
9.59 USD
6 months ago
May 08, 2024
Sell 47 K USD
Jackson Benjamin
General Counsel
- 4902
9.59 USD
6 months ago
May 08, 2024
Sell 63.2 K USD
Aerts Austin
Chief Financial Officer
- 6592
9.59 USD
6 months ago
May 08, 2024
Sell 115 K USD
Lindgardt Zhenya
Chief Executive Officer
- 11992
9.59 USD
6 months ago
May 08, 2024
Sell 47 K USD
Harrison Robert Gardner
Chief Information Officer
- 4902
9.59 USD
7 months ago
Mar 27, 2024
Sell 471 K USD
Boniface John J.
Chief Scientific Officer
- 48909
9.62 USD
7 months ago
Mar 28, 2024
Sell 221 K USD
Boniface John J.
Chief Scientific Officer
- 24474
9.04 USD
7 months ago
Mar 26, 2024
Sell 364 K USD
Lindgardt Zhenya
Chief Executive Officer
- 38899
9.37 USD
7 months ago
Mar 26, 2024
Sell 75.8 K USD
Aerts Austin
Chief Financial Officer
- 8092
9.37 USD
7 months ago
Mar 26, 2024
Sell 205 K USD
Boniface John J.
Chief Scientific Officer
- 21438
9.55 USD
7 months ago
Mar 25, 2024
Sell 202 K USD
Boniface John J.
Chief Scientific Officer
- 22163
9.1 USD
8 months ago
Mar 06, 2024
Sell 15 K USD
Boniface John J.
Chief Scientific Officer
- 1664
9.02 USD
8 months ago
Mar 06, 2024
Sell 4 K USD
Aerts Austin
Chief Financial Officer
- 444
9.02 USD
8 months ago
Mar 06, 2024
Sell 9.27 K USD
Kearney Paul
Chief Data Officer
- 1028
9.02 USD
8 months ago
Mar 06, 2024
Sell 19.3 K USD
Harrison Robert Gardner
Chief Information Officer
- 2138
9.02 USD
8 months ago
Mar 06, 2024
Sell 16.7 K USD
Jackson Benjamin
General Counsel
- 1856
9.02 USD
9 months ago
Feb 06, 2024
Sell 45.5 K USD
Jackson Benjamin
General Counsel
- 5665
8.03 USD
9 months ago
Feb 06, 2024
Sell 45.5 K USD
Boniface John J.
Chief Scientific Officer
- 5665
8.03 USD
9 months ago
Feb 06, 2024
Sell 40 K USD
Kearney Paul
Chief Data Officer
- 4984
8.03 USD
9 months ago
Feb 06, 2024
Sell 45.5 K USD
Harrison Robert Gardner
Chief Information Officer
- 5665
8.03 USD
9 months ago
Feb 06, 2024
Sell 225 K USD
Lindgardt Zhenya
Chief Executive Officer
- 27997
8.03 USD
9 months ago
Feb 06, 2024
Sell 78.6 K USD
Aerts Austin
Chief Financial Officer
- 9786
8.03 USD
11 months ago
Dec 07, 2023
Sell 52.2 K USD
Jackson Benjamin
General Counsel
- 10000
5.22 USD
11 months ago
Dec 07, 2023
Sell 24 K USD
Boniface John J.
Chief Scientific Officer
- 5000
4.8 USD
1 year ago
Jun 05, 2023
Sell 16.2 K USD
Harrison Robert Gardner
Chief Information Officer
- 5000
3.23 USD
2 years ago
Jul 26, 2022
Sell 2.22 K USD
Boniface John J.
Chief Scientific Officer
- 1000
2.22 USD
2 years ago
Jul 19, 2022
Sell 5.07 K USD
Boniface John J.
Chief Scientific Officer
- 2725
1.86 USD
2 years ago
Jul 12, 2022
Sell 5.01 K USD
Boniface John J.
Chief Scientific Officer
- 2725
1.84 USD
2 years ago
Jul 05, 2022
Sell 4.44 K USD
Boniface John J.
Chief Scientific Officer
- 2725
1.63 USD
2 years ago
Jun 28, 2022
Sell 1.72 K USD
Boniface John J.
Chief Scientific Officer
- 1000
1.72 USD
2 years ago
Jun 21, 2022
Sell 3.57 K USD
Boniface John J.
Chief Scientific Officer
- 2725
1.31 USD
2 years ago
Jun 14, 2022
Bought 9.6 K USD
Jackson Benjamin
General Counsel
+ 8000
1.2 USD
2 years ago
Jun 14, 2022
Sell 3.3 K USD
Boniface John J.
Chief Scientific Officer
- 2725
1.21 USD
2 years ago
Jun 07, 2022
Sell 3.54 K USD
Boniface John J.
Chief Scientific Officer
- 2725
1.3 USD
2 years ago
May 31, 2022
Sell 3.95 K USD
Boniface John J.
Chief Scientific Officer
- 2725
1.45 USD
2 years ago
May 24, 2022
Sell 4.2 K USD
Boniface John J.
Chief Scientific Officer
- 2725
1.54 USD
2 years ago
May 17, 2022
Sell 4.22 K USD
Boniface John J.
Chief Scientific Officer
- 2725
1.55 USD
2 years ago
May 10, 2022
Sell 5.37 K USD
Boniface John J.
Chief Scientific Officer
- 2725
1.97 USD
2 years ago
May 04, 2022
Sell 2.17 K USD
Boniface John J.
Chief Scientific Officer
- 1000
2.17 USD
2 years ago
May 03, 2022
Sell 5.91 K USD
Boniface John J.
Chief Scientific Officer
- 2725
2.17 USD
2 years ago
Apr 26, 2022
Sell 5.91 K USD
Boniface John J.
Chief Scientific Officer
- 2725
2.17 USD
2 years ago
Apr 19, 2022
Sell 5.67 K USD
Boniface John J.
Chief Scientific Officer
- 2725
2.08 USD
2 years ago
Apr 12, 2022
Sell 7.25 K USD
Boniface John J.
Chief Scientific Officer
- 2725
2.66 USD
2 years ago
Apr 05, 2022
Sell 3.02 K USD
Boniface John J.
Chief Scientific Officer
- 1000
3.02 USD
2 years ago
Mar 29, 2022
Sell 10.2 K USD
Boniface John J.
Chief Scientific Officer
- 2725
3.73 USD
2 years ago
Mar 22, 2022
Sell 10 K USD
Boniface John J.
Chief Scientific Officer
- 2725
3.68 USD
2 years ago
Mar 14, 2022
Sell 10.7 K USD
Boniface John J.
Chief Scientific Officer
- 2725
3.94 USD
7. News
Sera Prognostics to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum SALT LAKE CITY , Nov. 15, 2024 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21, 2024 at 4:00 p.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss Sera's latest achievements. prnewswire.com - 1 day ago
Sera Prognostics Inc (SERA) Q3 2024 Earnings Call Transcript Sera Prognostics Inc (NASDAQ:SERA ) Q3 2024 Results Conference Call November 7, 2024 5:00 PM ET Company Participants Peter DeNardo - IR Evguenia Lindgardt - President, CEO & Director Austin Aerts - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review Third Quarter Fiscal Year 2024 Results. [Operator Instructions] As a reminder, the call is being recorded for replay purposes. seekingalpha.com - 1 week ago
Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Lags Revenue Estimates Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.23 per share a year ago. zacks.com - 1 week ago
SERA PROGNOSTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS SALT LAKE CITY , Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2024 ended September 30, 2024. Recent Highlights: Data analysis for full Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study underway after database was locked in September and now seeking publication of results in connection with key pregnancy and maternal health conferences in early 2025 and manuscript submission to a quality peer-reviewed journal. prnewswire.com - 1 week ago
Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2024 Financial Results on November 6, 2024 SALT LAKE CITY , Oct. 28, 2024 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter fiscal year 2024 financial results on Wednesday, November 6, 2024, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. prnewswire.com - 2 weeks ago
Sera Prognostics to Present at H.C. Wainwright 26th Annual Global Investment Conference SALT LAKE CITY , Sept. 4, 2024 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the H.C. prnewswire.com - 2 months ago
Sera Prognostics, Inc. (SERA) Q2 2024 Earnings Call Transcript Sera Prognostics, Inc. (NASDAQ:SERA ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Peter DeNardo - CapComm Partners Zhenya Lindgardt - President & CEO Austin Aerts - CFO Conference Call Participants Andrew Brackmann - William Blair Dan Brennan - TD Cowen Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review second quarter fiscal year 2024 results. [Operator Instructions] As a reminder, this call is being recorded for replay purposes. seekingalpha.com - 3 months ago
Sera Prognostics to Participate in Panel Discussion at UBS Genomic Medicine Summit on August 14, 2024 SALT LAKE CITY , Aug. 8, 2024 /PRNewswire/ -- Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that its management team will participate in the following upcoming investor conference:  UBS Genomic Medicine Summit, August 13-14. President and Chief Executive Officer, Zhenya Lindgardt, will participate in a panel discussion: Future of Genetic Testing – Babies and Beyond, on August 14 at 8:00 a.m. prnewswire.com - 3 months ago
Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.34 per share a year ago. zacks.com - 3 months ago
SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS SALT LAKE CITY , Aug. 7, 2024 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2024 ended June 30, 2024. Recent Highlights: Publication of positive AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls) results in international peer-reviewed journal, Diagnostics , with coverage on front page of publication. prnewswire.com - 3 months ago
Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2024 Financial Results on August 7, 2024 SALT LAKE CITY , July 25, 2024 /PRNewswire/ -- Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report second quarter fiscal year 2024 financial results on Wednesday, August 7, 2024, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. prnewswire.com - 3 months ago
Sera Prognostics PreTRM® Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial Sera Prognostics Announces Publication of Positive AVERT PRETERM TRIAL Results in the International Peer-Reviewed Journal, Diagnostics SALT LAKE CITY , July 9, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the publication in Diagnostics, an international, peer-reviewed, open access journal on medical diagnosis, of the top-line results from the AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls), conducted at ChristianaCare in Wilmington, Delaware. PreTRM® test-and-treat strategy demonstrates statistically and clinically significant improvement in neonatal health outcomes and hospital length-of-stay Previously, Sera reported that both co-primary outcomes—reduction of severe neonatal morbidity or neonatal death; and decreased length of neonatal hospital stay—met their endpoints, and the improvements in outcome with a PreTRM® test-and-treat approach were statistically significant. prnewswire.com - 4 months ago
8. Profile Summary

Sera Prognostics, Inc. SERA

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 201 M
Dividend Yield 0.00%
Description Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Contact 2749 East Parleys Way, Salt Lake City, UT, 84109 https://seraprognostics.com
IPO Date July 15, 2021
Employees 55
Officers Mr. Robert G. Harrison Chief Information Officer Ms. Evguenia Lindgardt M.B.A. President, Chief Executive Officer & Director Mr. Austin Aerts Chief Financial Officer Dr. John J. Boniface Ph.D. Chief Scientific Officer Dr. Gregory C. Critchfield M.D., M.S. Executive Director Mr. Benjamin G. Jackson J.D. General Counsel Dr. Paul Kearney Ph.D. Chief Data Officer